Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03AND
|
|||
| Former ID |
DNCL002421
|
|||
| Drug Name |
RAF265
|
|||
| Synonyms |
RAF265; 927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1], [2] | |
| Company |
Novartis Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H16F6N6O
|
|||
| Canonical SMILES |
CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F
|
|||
| InChI |
1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)
|
|||
| InChIKey |
YABJJWZLRMPFSI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 927880-90-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16760016, 26544157, 50100093, 79191747, 87231167, 103694307, 104253490, 123051132, 123055402, 124757618, 125164422, 126661315, 126731472, 135723836, 135727478, 136348734, 136367589, 137275908, 137304097, 137304118, 143499710, 152234782, 152258150, 152344206, 160646987, 162011466, 162037791, 162202589, 163908009, 172914454, 174531387, 178102301, 180386850, 185990446, 223388540, 223685438, 224081157, 226980352, 242059961, 245765895, 248532827, 249871553, 251910728, 251971069, 252216175, 252300706, 252451617, 252615336
|
|||
| ChEBI ID |
CHEBI:91451
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5674). | |||
| REF 2 | ClinicalTrials.gov (NCT00304525) A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma. U.S. National Institutes of Health. | |||
| REF 3 | RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.